Skip to main content

Relapsing Remitting MS

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Cerecin
CerecinCO - Broomfield
1 program
Caprylic TriglycerideN/A1 trial
Active Trials
NCT01848327Completed124Est. Dec 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CerecinCaprylic Triglyceride

Clinical Trials (1)

Total enrollment: 124 patients across 1 trials

NCT01848327CerecinCaprylic Triglyceride

Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis

Start: Feb 2013Est. completion: Dec 2017124 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.